Other
Journal
News Categories
- Clinical Trials
- Research News
- Industry Trends
- Agency Actions
- Drug Safety Issues
- Approvals, Launches, & New Indications
- Health Care Reform
- Guidelines
FDA Sets Review Date for New COPD Drug, Anoro Ellipta
Approval decision expected in December (Feb. 19)
The FDA has accepted the new drug application (NDA) for an investigational once-daily LAMA/LABA combination medicine — umeclidinium bromide and vilanterol (UMEC/VI, GlaxoSmithKline/Theravance) — for patients with chronic obstructive pulmonary disease (COPD).
The Prescription Drug User Fee Act (PDUFA) goal date is December 18, 2013.
UMEC/VI — with the proposed brand name of Anoro — is a combination of two investigational bronchodilator molecules: umeclidinium bromide (formerly known as GSK573719, a long-acting muscarinic antagonist [LAMA]) and vilanterol (a long-acting beta2 agonist [LABA]). The combo drug is administered using the Ellipta inhaler.
Source: GSK; February 19, 2013.
